Prefilled drug-delivery systems and packaging solutions provider Vetter has expanded its secondary packaging capabilities at the Ravensburg site in Germany.
Vetter intends to develop an additional 2900m² of space at the Ravensburg site, which already has an existing area of around 6000m².
The new space, which is expected to be available by 2020, will be used for future secondary packaging operations.
The expansion will also include investments in modern testing and analysis methods. It will help the company to offer more extensive tests for autoinjectors starting in March 2019.
Vetter production and engineering senior vice president Bernd Stauss said: “Thanks to the modular use of manual, semi-automatic and fully automatic machines, we are able to individually package anything from small clinical to large commercial quantities and, therefore, react flexibly to changing customer structures and requirements.”
At present, the Ravensburg site includes advanced lines used for the packaging of various syringes, cartridges and vials.
Vetter offers labeling, blister packing, cartooning and serialization solutions, as well as advanced packaging solutions for the assembly of pens, auto-injectors and safety devices.
In October 2017, Vetter first announced plans to expand the secondary packaging capabilities at the Ravensburg facility.
The company announced the expansion plans to meet the growing customer needs and market demand for complex packaging solutions.
Vetter quality senior vice president Wolfgang Weikmann said: “State-of-the-art technologies and extensive know-how are bundled at Vetter. In this way, we create real value for our customers – high quality, compliance with regulatory requirements and user-friendly administration systems.”
Vetter said the increasing demand will allow it continue to expand its offering for complete solutions in the future and contribute with user-friendly solutions for patient safety.
Based in Ravensburg, Vetter is a contract development and manufacturing organization (CDMO) that operates production facilities in Germany and the US.
With around 4,400 employees, the company serves both large and small biotechnology and pharmaceutical customers.
The firm’s services range from early stage development including clinical manufacturing to commercial supply and multiple packaging solutions for vials, syringes and cartridges.